Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement. 2023;19(2):658–70.

Article  PubMed  Google Scholar 

Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118(1):5–36.

Article  CAS  PubMed  Google Scholar 

Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics. 2003;3(8):1486–94.

Article  CAS  PubMed  Google Scholar 

Huang YM, Ma YH, Gao PY, Wang ZB, Huang LY, Hou JH, et al. Plasma β(2)-microglobulin and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact older adults: the CABLE study. Alzheimer's Res Ther. 2023;15(1):69.

Article  CAS  Google Scholar 

Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci. 2004;5(7):521–31.

Article  CAS  PubMed  Google Scholar 

Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. Science (New York, NY). 2000;290(5499):2155–9.

Article  CAS  Google Scholar 

Smith LK, He Y, Park JS, Bieri G, Snethlage CE, Lin K, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med. 2015;21(8):932–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Zheng Q, Hong Y, Gao Y, Hu J, Lang M, et al. β(2)-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice. Nat Neurosci. 2023;26(7):1170–84.

Article  CAS  PubMed  Google Scholar 

van Westrhenen A, Smidt LC, Seute T, Nierkens S, Stork AC, Minnema MC, et al. Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol . 2018;182(3):384–403.

Article  PubMed  PubMed Central  Google Scholar 

Padovani A, Canale A, Schiavon L, Masciocchi S, Imarisio A, Risi B, et al. Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimers Dement . 2022;18(11):2167–75.

Article  CAS  PubMed  Google Scholar 

Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol. 2023;19(7):395–409.

Article  CAS  PubMed  Google Scholar 

Zhang PF, Hu H, Tan L, Yu JT. Microglia Biomarkers in Alzheimer’s Disease. Mol Neurobiol. 2021;58(7):3388–404.

Article  CAS  PubMed  Google Scholar 

Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.

Article  PubMed  Google Scholar 

Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17(4):201–7.

Article  CAS  PubMed  Google Scholar 

Suárez-Calvet M, Kleinberger G, Araque Caballero M, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466–76.

Article  PubMed  PubMed Central  Google Scholar 

Uddin MS, Lim LW. Glial cells in Alzheimer’s disease: From neuropathological changes to therapeutic implications. Ageing Res Rev. 2022;78:101622.

Article  CAS  PubMed  Google Scholar 

Bombeiro AL, Hell RC, Simões GF, Castro MV, Oliveira AL. Importance of major histocompatibility complex of class I (MHC-I) expression for astroglial reactivity and stability of neural circuits in vitro. Neurosci Lett. 2017;647:97–103.

Article  CAS  PubMed  Google Scholar 

Ignarro RS, Bombeiro AL, Chiarotto GB, Cartarozzi LP, Coser LO, Ghizoni E, et al. Interferon-beta induces major histocompatibility complex of class I (MHC-I) expression and a proinflammatory phenotype in cultivated human astrocytes. Differentiation. 2022;128:43–56.

Article  CAS  PubMed  Google Scholar 

Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte Biomarkers in Alzheimer’s Disease. Trends Mol Med. 2019;25(2):77–95.

Article  CAS  PubMed  Google Scholar 

Olsen M, Aguilar X, Sehlin D, Fang XT, Antoni G, Erlandsson A, et al. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease. Mol Imag Biol. 2018;20(4):605–14.

Article  CAS  Google Scholar 

Carrillo MC, Masliah E, editors. NIA-AA Revised Clinical Criteria for Alzheimer's Disease. Alzheimer's Association International Conference: ALZ; 2023.

Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nature Aging. 2024;4(2):247–60.

Article  CAS  PubMed  Google Scholar 

Wu C, Liu TC, Duan R, Yang L. β2‐microglobulin: An essential coaggregation factor with β‐amyloid in amyloid pathology. Brain-X. 2023;1(4):49.

Aisen PS, Petersen RC, Donohue M, Weiner MW. Alzheimer’s Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement. 2015;11(7):734–9.

Article  PubMed  Google Scholar 

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl. 2015;9(7–8):715–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, et al. CSF progranulin increases in the course of Alzheimer’s disease and is associated with sTREM 2, neurodegeneration and cognitive decline. EMBO Mol Med. 2018;10(12):e9712.

Article  PubMed  PubMed Central  Google Scholar 

Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517–26.

Article  PubMed  Google Scholar 

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero M, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69(10):1318–25.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

Article  PubMed  Google Scholar 

Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–82.

Article  CAS  PubMed  Google Scholar 

Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry. 2020;25(11):2932–41.

Article  CAS  PubMed  Google Scholar 

Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, et al. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematol Oncol. 2016;34(1):22–7.

Article